Cannabidiol medicine gets FDA approval, as the senior federal advisors on Thursday have unanimously recommended the Epidiolex, a drug which is an oral solution that cures critical norms of epilepsy.

The advisory committee of the U.S. Food and Drug Administration has recently recommended an approval for the synthetic versions of the medicine known as cannabidiol, which is the first ever drug derived from marijuana plant, to be prescribed in the United States. The new drug is also supposed to help in relieving certain types of cancer pains.


Cannabidiol is among over 80 effective cannabinoid chemicals, which is also known as CBD. The drug still does not resemble the tetrahydrocannabinol, i.e. THC and not producing high. The data received from the producer of the drug – GW Pharmaceuticals PLC, the biopharmaceutical company located in the United Kingdom.

A pharmacy clinical specialist, adjunct assistant professor and pharmacist, Shauna Garris from the Eshelman School of Pharmacy at the University of North Carolina, said in a statement that, “There have been side effects associated with it, and it appears a lot of the side effects were in conjunction with other medications, which is a concern, because most of those patients are on other medications. There are likely to be drug interactions, but that’s not uncommon for antiepileptic medications.”

Justin Gover, CEO at the GW Pharmaceuticals PLC, says, “We’re obviously very pleased by the unanimous recommendation in support of the approval of Epidiolex. It’s a very important milestone in the approval process. It’s a breakthrough in the field of epilepsy. It’s the first cannabis-based pharmaceutical to be approved by the FDA.”